Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort

Cancer research · Hepatocellular carcinoma

Atezolizumab‑Bevacizumab (AtezoBev) is an effective first‑line systemic therapy for hepatocellular carcinoma (HCC), producing overall survival and progression‑free survival rates comparable to the pivotal IMbrave150 trial.

Atezolizumab‑Bevacizumab (AtezoBev) was the first immunotherapy approved for hepatocellular carcinoma (HCC) in France, with initial trials primarily involving patients with viral‑related liver disease. This prospective study aimed to evaluate the efficacy of AtezoBev in a French HCC population predominantly affected by non‑viral liver disease. Data from 545 HCC patients treated with AtezoBev as first‑line systemic therapy were collected from 32 French centres in the CHIEF cohort between July 2020 and January 2023. Kaplan‑Meier analysis evaluated overall survival (OS) and progression‑free survival (PFS). Median OS was 23.1 months, with a 12‑month survival rate of 66%. OS was higher in BCLC‑B patients (27.8 months) compared to BCLC‑C (17.2 months, p = 0.0043) and in Child‑Pugh A (26.4 months) compared to Child‑Pugh B (10.6 months, p < 0.001). Median PFS was 5.2 months, with BCLC‑B patients showing significantly longer PFS (6.7 months vs. 3.7 months for BCLC‑C, p = 0.05). Real‑world data from the CHIEF cohort demonstrate AtezoBev's effectiveness in a large French HCC population, showing survival and response rates comparable to the IMbrave150 study.

These findings validate AtezoBev as an effective therapeutic option in routine clinical practice across diverse HCC patient populations, supporting its use beyond the settings of clinical trials.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals